Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 369, Issue 1, pp 89–104 | Cite as

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms



The cytochrome P450s are responsible for about 75% of phase I dependent drug metabolism and for the metabolism of a huge amount of dietary constituents and endogenous chemicals. The human has 59 active genes, and 6 of those encode important drug metabolising enzymes. About 40% of cytochrome P450 dependent drug metabolism is catalysed by polymorphic enzymes and such drug P450 interactions are frequently seen in adverse drug reaction reports. In this contribution an update of human cytochrome P450 enzymology and pharmacogenetics is given with particular emphasis on CYP1B1, CYP2B6, CYP2E1 and CYP3As.


Poor metabolizers Adverse drug reactions Genetic polymorphism Haplotypes Cancer drugs Ultrarapid metabolizers 


  1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707–715PubMedGoogle Scholar
  2. Afzelius L, Zamora I, Ridderstrom M, Andersson TB, Karlen A, Masimirembwa CM (2001) Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol 59:909–919PubMedGoogle Scholar
  3. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M (2002) Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 61:586–594PubMedGoogle Scholar
  4. Andersson TB, Sjoberg H, Hoffmann KJ, Boobis AR, Watts P, Edwards RJ, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Goldfarb PS, Lewis DF, Corcos L, Guillouzo A, Taavitsainen P, Pelkonen O (2001) An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab Dispos 29:712–720PubMedGoogle Scholar
  5. Backlund M, Mkrtchian S, Johansson I, Ingelman-Sundberg M (1997) Signal transduction mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells. J Biol Chem 272:31755–31763CrossRefPubMedGoogle Scholar
  6. Badger TM, Ronis MJ, Ingelman-Sundberg M, Hakkak R (1995) Inhibition of CYP2E1 activity does not abolish pulsatile urine alcohol concentrations during chronic alcohol infusions. Eur J Biochem 230:914–919PubMedGoogle Scholar
  7. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210–258Google Scholar
  8. Cosme J, Johnson EF (2000) Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 275:2545–2553CrossRefPubMedGoogle Scholar
  9. Crespi CL, Penman BW, Steimel DT, Smith T, Yang CS, Sutter TR (1997) Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Mutagenesis 12:83–89PubMedGoogle Scholar
  10. Danielson PB, MacIntyre RJ, Fogleman JC (1997) Molecular cloning of a family of xenobiotic-inducible drosophilid cytochrome P450s: evidence for involvement in host-plant allelochemical resistance. Proc Natl Acad Sci USA 94:10797–10802CrossRefPubMedGoogle Scholar
  11. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095PubMedGoogle Scholar
  12. De Waziers I, Garlatti M, Bouguet J, Beaune PH, Barouki R (1995) Insulin down-regulates cytochrome P450 2B and 2E expression at the post-transcriptional level in the rat hepatoma cell line. Mol Pharmacol 47:474–479PubMedGoogle Scholar
  13. De Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37:485–505PubMedGoogle Scholar
  14. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386–392PubMedGoogle Scholar
  15. Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190–194PubMedGoogle Scholar
  16. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, Khan KK, He YA, Halpert JR, Wojnowski L (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447–458PubMedGoogle Scholar
  17. Ekins S, Wrighton SA (1999) The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31:719–754CrossRefPubMedGoogle Scholar
  18. Ekins S, VandenBranden M, Ring BJ, Wrighton SA (1997) Examination of purported probes of human CYP2BG. Pharmacogenetics 7:165–179PubMedGoogle Scholar
  19. Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253–1259PubMedGoogle Scholar
  20. Ekins S, Stresser DM, Williams JA (2003) In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 24:161–166CrossRefPubMedGoogle Scholar
  21. Eliasson E, Johansson I, Ingelman-Sundberg M (1988) Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures. Biochem Biophys Res Commun 150:436–443PubMedGoogle Scholar
  22. Eliasson E, Johansson I, Ingelman-Sundberg M (1990) Substrate-, hormone-, and cAMP-regulated cytochrome P450 degradation. Proc Natl Acad Sci USA 87:3225–3229PubMedGoogle Scholar
  23. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491CrossRefPubMedGoogle Scholar
  24. Fairbrother KS, Grove J, de Waziers I, Steimel DT, Day CP, Crespi CL, Daly AK (1998) Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 8:543–552PubMedGoogle Scholar
  25. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–1230Google Scholar
  26. Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM (2001) Evaluation of the contribution of cytochrome p450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 29:1123–1129PubMedGoogle Scholar
  27. Floyd MD, Gervasini G, Masica AL, Mayo G, Alfred RN, George Jr L, Kolari Bhat MD, Kim RB, Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of Midazolam in European- and African-American men and women. Pharmacogenetics 13:595–606CrossRefPubMedGoogle Scholar
  28. Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, Azuma J (2000) The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 380:303–308CrossRefPubMedGoogle Scholar
  29. Gebhardt AC, Lucas D, Menez JF, Seitz HK (1997) Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 26:957–961PubMedGoogle Scholar
  30. Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587CrossRefPubMedGoogle Scholar
  31. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111–121PubMedGoogle Scholar
  32. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306PubMedGoogle Scholar
  33. Gibbs MA, Thummel KE, Shen DD, Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180–187PubMedGoogle Scholar
  34. Gillam EM, Wunsch RM, Ueng YF, Shimada T, Reilly PE, Kamataki T, Guengerich FP (1997) Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5’ modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch Biochem Biophys 346:81–90CrossRefPubMedGoogle Scholar
  35. Gonzalez FJ, Kimura S (2003) Study of P450 function using gene knockout and transgenic mice. Arch Biochem Biophys 409:153–158CrossRefPubMedGoogle Scholar
  36. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear receptor PXR. Mol Pharmacol 60:427–431PubMedGoogle Scholar
  37. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83–90PubMedGoogle Scholar
  38. Guengerich FP (1995) Human cytochrome P-450 enzymes. In: Ortiz de Montellano PR (ed) Cytochrome P-450, 2nd edn. Plenum, New York, pp 473–535Google Scholar
  39. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17PubMedGoogle Scholar
  40. Hakkola J, Pasanen M, Purkunen R, Saarikoski S, Pelkonen O, Mäenpää J, Rane A, Raunio H (1994) Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol 48:59–64PubMedGoogle Scholar
  41. Harlow GR, Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci USA 95:6636–6641CrossRefPubMedGoogle Scholar
  42. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T (1993) Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 218:585–595PubMedGoogle Scholar
  43. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR (1996) 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 93:9776–9781PubMedGoogle Scholar
  44. Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, Ingelman-Sundberg M (2001) CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson’s disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 29:1480–1484PubMedGoogle Scholar
  45. Honkakoski P, Negishi M (2000) Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 347:321–337CrossRefPubMedGoogle Scholar
  46. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–1479CrossRefPubMedGoogle Scholar
  47. Hu Y, Oscarson M, Johansson I, Yue Q-Y, Dahl ML, Tabone M, Arinco S, Albano E, Ingelman-Sundberg M (1997) Genetic polymorphism of the human CYP2E1—characterization of two variant alleles. Mol Pharmacol 51:370–376PubMedGoogle Scholar
  48. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M (1999) Structural and functional characterization of the 5’-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 263:286–293CrossRefPubMedGoogle Scholar
  49. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, Burk O (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454–1459PubMedGoogle Scholar
  50. Ingelman-Sundberg M (2001) Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250:186–200Google Scholar
  51. Ingelman-Sundberg M, Johansson I, Penttila KE, Glaumann H, Lindros KO (1988) Centrilobular expression of ethanol-inducible cytochrome P-450 (IIE1) in rat liver. Biochem Biophys Res Commun 157:55–60PubMedGoogle Scholar
  52. Ingelman-Sundberg M, Oscarson M, McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualised drug treatment. Trends Pharmacol Sci 20:342–349PubMedGoogle Scholar
  53. Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW (2000) Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics 10:91–93CrossRefPubMedGoogle Scholar
  54. Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S, Nebert DW (2001) Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles. Cancer Epidemiol Biomarkers Prev 10:1307–1308Google Scholar
  55. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387–412PubMedGoogle Scholar
  56. Iwahori T, Matsuura T, Maehashi H, Sugo K, Saito M, Hosokawa M, Chiba K, Masaki T, Aizaki H, Ohkawa K, Suzuki T (2003) CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 37:665–673CrossRefPubMedGoogle Scholar
  57. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, Ando M (2003) Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398–403CrossRefPubMedGoogle Scholar
  58. Johansson I, Lindros KO, Eriksson H, Ingelman-Sundberg M (1990) Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. Biochem Biophys Res Commun 173:331–338PubMedGoogle Scholar
  59. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825–11829PubMedGoogle Scholar
  60. Jover R, Bort R, Gomez-Lechon MJ, Castell JV (2001) Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 33:668–675CrossRefPubMedGoogle Scholar
  61. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716–727PubMedGoogle Scholar
  62. Kinirons MT, O’Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, Wilkinson GR (1999) Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 66:224–231Google Scholar
  63. Kliewer SA, Lehmann JM, Milburn MV, Willson TM (1999) The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog Horm Res 54:345–367PubMedGoogle Scholar
  64. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, Wojnowski L (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108–1114CrossRefPubMedGoogle Scholar
  65. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391PubMedGoogle Scholar
  66. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399–415PubMedGoogle Scholar
  67. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR (2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105:1067–1075PubMedGoogle Scholar
  68. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–1023PubMedGoogle Scholar
  69. Le Jossic C, Glaise D, Corcos L, Diot C, Dezier JF, Fautrel A, Guguen-Guillouzo C (1996) Trans-acting factors, detoxication enzymes and hepatitis B virus replication in a novel set of human hepatoma cell lines. Eur J Biochem 238:400–409PubMedGoogle Scholar
  70. McCarver DG, Byun R, Hines RN, Hichme M, Wegenek W (1998) A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 152:276–281CrossRefPubMedGoogle Scholar
  71. McKay JA, Melvin WT, Ah-See AK, Ewen SW, Greenlee WF, Marcus CB, Burke MD Murray GI (1995) Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett 374:270–272CrossRefPubMedGoogle Scholar
  72. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME (1995) Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36:259–267PubMedGoogle Scholar
  73. McLellan RA, Oscarson M, Hidestrand M, Leidvik B, Jonsson E, Otter C, Ingelman-Sundberg M (2000) Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch Biochem Biophys 378:175–181CrossRefPubMedGoogle Scholar
  74. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA (2000) St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500–7502PubMedGoogle Scholar
  75. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57:3026–3031PubMedGoogle Scholar
  76. Murray GI, Melvin WT, Greenlee WF, Burke MD (2001) Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41:297–316PubMedGoogle Scholar
  77. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, Kadlubar FF (2001) In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem 49:229–236PubMedGoogle Scholar
  78. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42PubMedGoogle Scholar
  79. Neve EP, Ingelman-Sundberg M (2001) Identification and characterization of a mitochondrial targeting signal in rat cytochrome P450 2E1 (CYP2E1). J Biol Chem 276:11317–11322CrossRefPubMedGoogle Scholar
  80. Neve EPA, Ingelman-Sundberg M (2000) Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane. J Biol Chem 275:17130–17135CrossRefPubMedGoogle Scholar
  81. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Ishizaki T, Asada A (2001) Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 51:281–285CrossRefPubMedGoogle Scholar
  82. Ohmori S, Nakasa H, Asanome K, Kurose Y, Ishii I, Hosokawa M, Kitada M (1998) Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta 1380:297–304CrossRefPubMedGoogle Scholar
  83. Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, Tohyama C, Krust A, Mimura J, Chambon P, Yanagisawa J, Fujii-Kuriyama Y, Kato S (2003) Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423:545–550CrossRefPubMedGoogle Scholar
  84. Oinonen T, Lindros KO (1998) Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J 329:17–35PubMedGoogle Scholar
  85. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52:1034–1040PubMedGoogle Scholar
  86. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373–388PubMedGoogle Scholar
  87. Pascussi JM, Jounaidi Y, Drocourt L, Domergue J, Balabaud C, Maurel P, Vilarem MJ (1999) Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem Biophys Res Commun 260:377–381CrossRefPubMedGoogle Scholar
  88. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203–1253CrossRefPubMedGoogle Scholar
  89. Pelkonen O, Boobis A, Kremers P, Ingelman-Sundberg M, Rane A (2001a) Interindividual variation of P450 enzymes in vitro and its causes. In: Pacifici G, Pelkonen O (eds) Interindividual variability in human drug metabolism. Taylor and Francis, London, pp 269–332Google Scholar
  90. Pelkonen O, Myllynen P, Taavitsainen P, Boobis AR, Watts P, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF (2001b) Carbamazepine: a ‘blind’ assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31:321–343CrossRefPubMedGoogle Scholar
  91. Peter R, Böcker RG, Beaune PH, Iwasaki M, Guengerich FP, Yang C-S (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem Res Toxicol 3:566–573PubMedGoogle Scholar
  92. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270–2279CrossRefPubMedGoogle Scholar
  93. Rae JM, Soukhova NV, Flockhart DA, Desta Z (2002) Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30:525–530CrossRefPubMedGoogle Scholar
  94. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, Tyndale RF (2000) Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58:747–755PubMedGoogle Scholar
  95. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 29:413–580PubMedGoogle Scholar
  96. Rivera SP, Saarikoski ST, Hankinson O (2002) Identification of a novel dioxin-inducible cytochrome P450. Mol Pharmacol 61:255–259CrossRefPubMedGoogle Scholar
  97. Roberts BJ (1997) Evidence of proteasome-mediated cytochrome P-450 degradation. J Biol Chem 272:9771–9778PubMedGoogle Scholar
  98. Roberts BJ, Song BJ, Soh Y, Park SS, Shoaf SE (1995) Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J Biol Chem 270:29632–29635CrossRefPubMedGoogle Scholar
  99. Robin MA, Anandatheerthavarada HK, Fang JK, Cudic M, Otvos L, Avadhani NG (2001) Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity. J Biol Chem 276:24680–24689CrossRefPubMedGoogle Scholar
  100. Robin MA, Anandatheerthavarada HK, Biswas G, Sepuri NB, Gordon DM, Pain D, Avadhani NG (2002) Bimodal targeting of microsomal CYP2E1 to mitochondria through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation. J Biol Chem 277:40583–40593CrossRefPubMedGoogle Scholar
  101. Ronis MJJ, Lindros KO, Ingelman-Sundberg M (1996) The cytochrome P4502E subfamily. In: Ioannides I (ed) Cytochromes P450, pharmacological and toxicological aspects. CRC Press, Boca Raton, pp 211–239Google Scholar
  102. Roy P, Tretyakov O, Wright J, Waxman DJ (1999) Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 27:1309–1318PubMedGoogle Scholar
  103. Rylander T, Neve EPA, Ingelman-Sundberg M, Oscarson M (2001) Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1) Biochem Biophys Res Commun 281:529–535Google Scholar
  104. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423PubMedGoogle Scholar
  105. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, Sutter TR (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56:2979–2984PubMedGoogle Scholar
  106. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20:1607–1613CrossRefPubMedGoogle Scholar
  107. Simi A, Ingelman-Sundberg M (1999) Post-translational inhibition of cytochrome P-450 2E1 expression by chlomethiazole in Fao hepatoma cells. J Pharmacol Exp Ther 289:847–852PubMedGoogle Scholar
  108. Simonsson US, Jansson B, Hai TN, Huong DX, Tybring G, Ashton M (2003) Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74:32–43CrossRefPubMedGoogle Scholar
  109. Smith G, Wolf CR, Deeni YY, Dawe RS, Evans AT, Comrie MM, Ferguson J, Ibbotson SH (2003) Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 361:1336–1343CrossRefPubMedGoogle Scholar
  110. Song BJ, Veech RL, Park SS, Gelboin HV, Gonzalez FJ (1989) Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 264:3568–3572PubMedGoogle Scholar
  111. Stoilov I, Akarsu AN, Sarfarazi M (1997) Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21’. Human Mol Genet 6:641–647CrossRefGoogle Scholar
  112. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, Or M, Lewis RA, Ozdemir N, Brice G, Aktan SG, Chevrette L, Coca-Prados M, Sarfarazi M (1998) Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 62:573–584PubMedGoogle Scholar
  113. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274:6043–6046CrossRefPubMedGoogle Scholar
  114. Tang YM, Wo YY, Stewart J, Hawkins AL, Griffin CA, Sutter TR, Greenlee WF (1996) Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem 271:28324–28330PubMedGoogle Scholar
  115. Thummel KE, Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389–430PubMedGoogle Scholar
  116. Van Schaik RHN, van der Werf M, van der Heiden IP, Dorrestein S, Brosens Thiadens RA, van Iperen N, van Fessem M, van Vliet M, de Wildt SN, van den Anker JN, Lindemans J (2003) CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population. Clin Pharmacol Ther 73:42Google Scholar
  117. Weinshilboum R (2003) Genomic medicine: inheritance and drug response. N Engl J Med 348:529–537CrossRefPubMedGoogle Scholar
  118. Werlinder V, Backlund M, Zhukov A, Ingelman-Sundberg M (2001) Transcriptional and post-translational regulation of CYP1A1 by primaquine. J Pharmacol Exp Ther 297:206–214PubMedGoogle Scholar
  119. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5’-upstream regulatory region. Biochem Biophys Res Commun 259:201–205PubMedGoogle Scholar
  120. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, Oscarson M (2001) Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281:1349–1355CrossRefPubMedGoogle Scholar
  121. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755–761CrossRefPubMedGoogle Scholar
  122. Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5:121–131PubMedGoogle Scholar
  123. Wrighton SA, Vandenbranden M (1989) Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. Arch Biochem Biophys 268:144–151PubMedGoogle Scholar
  124. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, Iga T (2001) Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 29:887–890PubMedGoogle Scholar
  125. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert DO, Schwab M, Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573–585CrossRefPubMedGoogle Scholar
  126. Zanger UM, Fischer J, Klein K, Lang T (2002) Detection of single nucleotide polymorphisms in CYP2B6 gene. Methods Enzymol 357:45–53PubMedGoogle Scholar
  127. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804–809PubMedGoogle Scholar
  128. Zhukov A, Ingelman-Sundberg M (1999) Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase. Biochem J 340:453–458CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Division of Molecular Toxicology, Institute of Environmental MedicineKarolinska InstitutetStockholmSweden

Personalised recommendations